Los puntos clave no están disponibles para este artículo en este momento.
In this trial, LSG and LRYGB are equally efficient regarding weight loss, quality of life, and complications up to 3 years postsurgery. Improvement of comorbidities is similar except for gastro-esophageal reflux disease and dyslipidemia that appear to be more successfully treated by LRYGB.
Peterli et al. (Tue,) studied this question.